<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">In conclusion, forodesine has clinically meaningful single-agent activity, with durable responses, and a manageable safety profile in patients with relapsed PTCL. Compared with PTCL options that require intravenous infusion with frequent or prolonged clinic visits, the oral formulation makes forodesine easier to administer and, in turn, may be more convenient and less burdensome to patients. New therapeutic strategies with forodesine, including combination therapy, are being considered.</p>
